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Background: The leading cause of mortality due to pulmonary arterial hypertension (PAH) is failure of the cardiac
right ventricle. It has long been hypothesized that during the development of chronic cardiac failure the heart
becomes energy deprived, possibly due to shortage of oxygen at the level of cardiomyocyte mitochondria. However,
direct evaluation of oxygen tension levels within the in vivo right ventricle during PAH is currently lacking. Here we
directly evaluated this hypothesis by using a recently reported technique of oxygen-dependent quenching of delayed
fluorescence of mitochondrial protoprophyrin IX, to determine the distribution of mitochondrial oxygen tension
(mitoPO2) within the right ventricle (RV) subjected to progressive PAH.
Methods: PAH was induced through a single injection of monocrotaline (MCT). Control (saline-injected), compensated
RV hypertrophy (30 mg/kg MCT; MCT30), and RV failure (60 mg/kg MCT; MCT60) rats were compared 4 wk after
treatment. The distribution of mitoPO2 within the RV was determined in mechanically-ventilated, anaesthetized
animals, applying different inspired oxygen (FiO2) levels and two increment dosages of dobutamine.
Results: MCT60 resulted in RV failure (increased mortality, weight loss, increased lung weight), MCT30 resulted in
compensated RV hypertrophy. At 30% or 40% FiO2, necessary to obtain physiological arterial PO2 in the diseased
animals, RV failure rats had significantly less mitochondria (15% of total mitochondria) in the 0-20 mmHg mitoPO2
range than hypertrophied RV rats (48%) or control rats (54%). Only when oxygen supply was reduced to 21% FiO2,
resulting in low arterial PO2 for the MCT60 animals, or when oxygen demand increased with high dose dobutamine,
the number of failing RV mitochondria with low oxygen became similar to control RV. In addition, metabolic enzyme
analysis revealed similar mitochondrial mass, increased glycolytic hexokinase activity following MCT, with increased
lactate dehydrogenase activity only in compensated hypertrophied RV.
Conclusions: Our novel observation of increased mitochondrial oxygenation suggests down-regulation of in vivo
mitochondrial oxygen consumption, in the absence of hypoxia, with transition towards right ventricular failure
induced by pulmonary arterial hypertension.
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Severe pulmonary arterial hypertension (PAH) is asso-
ciated with poor prognosis. The development of PAH
induces hypertrophy of the right ventricle (RV) that
often transition into RV failure. Heart failure of the right
ventricle during chronic PAH is the most common cause
of mortality in severe PAH, with metabolic and energetic
derangements as a prominent signature of heart failure
[1]. In the hypertrophied and failing heart, the increased
systolic wall stress in the ventricular wall would be ex-
pected to increase the energy demand, whereas the in-
creased size of the cardiomyocyte and the decreased
capillary density is anticipated to diminish the oxygen
supply. These observations have led to the suggestion that
there is an imbalance between oxygen/energy supply-
demand in the hypertrophied heart, which possibly con-
tributes to the transition to the decompensated, failing
heart [2]. The often observed decreased PCr/ATP ratio,
increased reliance on glucose metabolism and elevated
lactate levels [3,4] are in support of such a mismatch,
and suggest that the failing heart is an engine out of fuel
[5]. One possible cause for reduced ATP production in
the failing heart could be the lack of enough oxygen
provided to the mitochondria. Hitherto, this question
has only been indirectly evaluated through 1H NMR
techniques which estimate the ratio of deoxygenated to
oxygenated myoglobin. Examining several heart failure
models using this technique it was concluded that re-
duced oxygen availability does not play a role in heart
failure [3,6,7]. The sensitivity of this technique, how-
ever, is such that a signal can only be detected when the
entire myocardial tissue investigated reaches an intra-
cellular PO2 < 20 mmHg [3]. Since the mean PO2 at the
level of the mitochondria in intact healthy heart is
approximately 35 mmHg [8], the myoglobin technique
can only detect large decreases (>40%) in myocardial
oxygenation. Thus, relatively smaller decreases or any
increase in myocardial oxygenation will go unnoticed
with the 1H NMR technique. In addition, the mitoPO2
within the heart is highly heterogeneous, such that at
a mean mitoPO2 of 35 mmHg a significant portion
of mitochondria may have a mitoPO2 < 20 mmHg [8].
These mitochondria may become oxygen-limited, as
studies in isolated mitochondria have demonstrated
decreased oxygen consumption when PO2 drops down
in the 10-20 mmHg range [9,10].
Alternatively, ATP production could also diminish due
to intrinsic mitochondrial remodelling resulting in sup-
pression of mitochondrial energy production. Suppression
of mitochondrial energy metabolism through mitochon-
drial metabolic reprogamming together with increased
glycolysis was recently proposed as intrinsic mechanism
in the development of heart failure [11]. In addition, mito-
chondrial oxygen consumption may also be inhibitedthrough competition of increased levels of NO with O2 at
the level of cytochrome c oxidase during hypertrophy and
heart failure [12]. Irrespective of the precise mechanism,
suppression of mitochondrial energy metabolism should
be reflected by elevated mitoPO2. Therefore, the non-
invasive determination of oxygenation within the intact
heart may shed light on the important question whether
the development of cardiac hypertrophy and the subse-
quent transition to heart failure is associated with in-
creased hypoxia or suppressed mitochondrial energy
production. Since mitochondria are the principal sites of
ATP generation, they are the ideal site of determining the
prevailing oxygen tension. Our group recently developed a
non-invasive technique which allows, for the first time,
the quantitative determination of the distribution of mito-
chondrial PO2 within the heart [8,13-15]. Validation stud-
ies in several cell lines have demonstrated that the delayed
fluorescence signal and its lifetime is determined by mito-
chondrial PpIX and the amount of mitochondrial oxygen
present [15]. Subsequent studies, extending from cells to
isolated organs to the in vivo organ for liver [14] and heart
[8], validated that the lifetime of the specific delayed fluor-
escence signal measured in all these conditions did indeed
reflect the mitochondrial oxygen tension. In the current
project we now apply this novel technique to examine the
in vivo mitochondrial oxygenation in the right ventricle
during the development of cardiac hypertrophy and failure
due to pulmonary arterial hypertension.
Methods
The experiments of this study were approved by the
ethical committee for animal subjects of the Academic
Medical Center at the University of Amsterdam and
Erasmus Medical Center at the University of Rotterdam.
Care and handling of the animals were in accordance
with the guidelines for Institutional and Animal Care
and Use Committees. Male Wistar rats (n = 22; 7-8 wk,
180-220 g, Harlan, Netherlands) were attributed to
either receive an intraperitoneal injection of monocro-
taline (MCT) at a dose of 30 mg/kg (n = 7) or 60 mg/kg
(n = 9), or normal saline (n = 6). Body weight was moni-
tored for the next 28 days.
Animal preparation
Invasive measurements were performed on 28 days after
intraperitoneal injection. We selected 28 days post MCT
administration, because in our hands RV heart failure
and sharp reductions in body weight then starts to
develop before most of the animals die. Premedication
was done with subcutaneous buprenorphine (Temgesic,
Schering-Plough, Netherlands; 0.05 mg/kg), 30 minutes
before intraperitoneal injection of NaOH-buffered 5-
aminolevulinic acid (ALA; 200 mg/kg). ALA was admin-
istered to increase mitochondrial PpIX concentration.
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equal dose of buprenorphine was administered. Anesthesia
was induced by isoflurane. 5% isoflurane in oxygen was
used for controls, and 3% isoflurane for monocrotaline
treated animals (pilot experiments showed increased sensi-
tivity of MCT animals to isoflurane induction). Anesthesia
was then similarly maintained for all groups by pento-
barbital at 60 mg/kg initial dose followed hourly by 60%
of the initial dose. Body temperature was rectally mea-
sured and kept at 37 ± 0.5°C with a heating pad. The
airway was secured by tracheal intubation following
which the animals were ventilated in pressure-controlled
mode at 40% oxygen with a positive end-expiratory
pressure of 2.5 mbar. The ventilator settings were
checked by capnography and blood gases. The carotid
artery and jugular vein were cannulated for blood pres-
sure and heart rate monitoring and infusion of fluid
(Ringer’s lactate at 10 ml/kg/h) and drugs, respectively.
A median upper laparotomy was performed, the dia-
phragm incised and the pericardium opened. The fiber
optic probe for mitoPO2 measurements was positioned
transdiaphragmally at approximately 1 mm from the right
ventricle (RV) of the beating heart.
Experimental protocol
The measurements of the mitochondrial oxygen partial
pressures (mitoPO2) were started at 2 hours after ALA
injection, to allow sufficient increases in mitochondrial
PpIX for the delayed fluorescence measurements. The
experimental protocol consisted in the measurement of
mitoPO2 at varying inspiratory oxygen fraction (40%,
30%, 21%, 40%) and at two dosages of dobutamine (Cen-
trafarm, Etten-Leur, Netherlands), 2.5 μg/kg/min and
5 μg/kg/min. All measurements during the infusion of
dobutamine were made at an inspiratory oxygen fraction
of 40%. The 30 and 40% FiO2 are necessary to prevent
non-physiological low arterial oxygen tension in the
MCT animals, probably because in these animals the
lung damage impaired ventilation/perfusion matching
within the lungs. Every step of the protocol was main-
tained for 10 minutes before any measurement was per-
formed. At each step 0.2 ml blood was sampled from
the cannulated carotid artery and analyzed with a blood
gas analyzer (ABL800 flex, Radiometer, Copenhagen).
At the end of the experiment, right ventricular pressure
was measured by transmyocardial puncture using a 23
gauge needle connected to a pressure transducer and
automatic flushing system. After termination of the
experiment, heart and lungs were excised and weighed.
The heart was subsequently dissected into right and left
ventricle, after a small apical part of the heart was
removed for histological and biochemical processing.
The tissue was immediately frozen in liquid nitrogen
and stored at -80°C.Mitochondrial PO2 measurements
The principle and setup for in vivo mitoPO2 measure-
ments was previously reported [8,14,15], and a detailed
description of the used setup was recently published
[13]. In brief, mitochondrial oxygen tension is measured
with the Protoporphyrin IX (PpIX) – Triplet State Lifetime
technique. Application of ALA results in the mitochondrial
accumulation of PpIX. PpIX displays oxygen-dependent
quenching of delayed fluorescence lifetime. Mitochondrial
PpIX is excited at 510 nm through an excitation fiber
coupled to a tunable laser, and delayed fluorescence at
630-700 nm is detected by an emission fiber connected to
a gated microchannel plate photomultiplier. A PC-based
data-acquisition system sampled the signal at 1 MHz
and averaged 64 laser pulses (repetition rate 20 Hz)
prior to analysis. The delayed fluorescence signal was
then used to recover the different mitoPO2 histograms
from fitting the signal by a sum of rectangular distribu-
tions of delayed fluorescence lifetimes. Three separate
series of 64 pulses were analyzed and averaged at each
experimental condition.Tissue analysis
Three sections of the apex, 5 μm thick, were cut in a
cryostat, collected on slides, fixed in 4% formaldehyde,
stained with hematoxylin and eosin, dehydrated and
mounted in Entellan (Merck). Images were obtained
with a 40x objective, and cross-sectional area of individ-
ual myocytes was determined at the level of the nucleus
using Image J (imagej.nih.gov/ij/), taking the pixel to
aspect ratio into account [16]. Within each section the
cross-sectional area was determined for 6-12 cardiomyo-
cytes. RV and LV homogenates were obtained by grinding
the frozen tissue into powder in liquid nitrogen, dissolving
the powder in 1 ml ice-cold homogenization buffer (0.5%
Triton X-100, 250 mM sucrose, 20 mM Hepes (pH 7.4),
10 mM KCl, 1.5 mM MgCl2, 1 mM EDTA, 1 mM dithio-
threitol, 0.1 mM PMSF, 5 μg/ml leupeptin and aprotinin
and 1 μg/ml pepstatin), 15 min incubation, sonication
and finally 1 min 10,000 g centrifugation to obtain the
supernatant. Citrate synthase activity, as marker of
mitochondrial content, and hexokinase and lactate de-
hydrogenase activities, as markers of glycolysis, were
determined in the supernatant according to published
spectrophotometric techniques [17,18], and normalised
to protein content (Bradford technique).Statistics
The data are presented as mean ± SEM. One way ana-
lysis was performed followed by Fisher’s probable least-
significant-difference post hoc analysis between groups
(SPSS Statistics 20). A value of P < 0.05 was considered
statistically significant.
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General characterization of MCT animals
Two 60 mg/kg MCT animals (MCT60) died before 4
wk. One 30 mg/kg (MCT30) and one MCT60 animal
died at induction of anesthesia. 6 animals of each
MCT group completed the experimental protocol. Body
weight developed to a similar degree for all three
groups up to 3 wk. Thereafter the MCT60 group
started to lose weight, such that at 4 wk body weight
was significantly reduced for the MCT60 group as
compared to control and MCT30 (Figure 1A). In
addition, MCT60 demonstrated increased lung weight
at 4 wk (Figure 1B). RV hypertrophy was similar in both
MCT groups (Figure 1C and D), whereas peak RV pres-
sure almost tripled in MCT60 rats (Figure 1E). These
data indicate compensated RV hypertrophy for the
MCT30 group, and the start of right heart failure for
the MCT60 group.D
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Physiology of the animals during the experimental
protocol is depicted in Figure 2. Although there was a
trend that MCT in general lowers hemodynamics in
the anesthetized animals, this only reached significance
for heart rates (Figure 2A) during the dobutamine infu-
sions; no significant depression of MAP (Figure 2B)
was observed following MCT treatment. Reducing FiO2
was paralleled with reductions in arterial PO2 for both
control and MCT animals, whereas arterial PO2 was in
most conditions significantly higher for control versus
MCT animals (Figure 2C). At 30% FiO2 the arterial
oxygen tension was still at a normal physiological level
(~100 mmHg) for the MCT60 group, whereas at 21%
FiO2 arterial oxygen tension dropped below normal
arterial oxygenation levels (<70 mmHg), indicating that
at least 30% FiO2 was necessary to maintain physio-
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hemoglobin in MCT animals at 21% FiO2 (Figure 2D).
Mitochondrial oxygen tension
FiO2-dependent PpIX delayed fluorescence signals were
obtained in vivo from the RV of control and MCT animals
and the distribution of mitoPO2 histograms determined
(Figure 3). At 40% FiO2, the distribution of mitoPO2
showed a rightward shift towards higher values for the
MCT60 RV as compared to control RV (Figure 3A). The
fraction of mitochondria with PO2 values below 20 mm
Hg, assumed to be oxygen limited, was similar between
control (54 ± 11%) and the MCT30 group (48 ± 12).
However, significant less mitochondria within the RV of
the MCT60 group (15 ± 10%) were observed in this low
oxygen range as compared to control (Figure 3B). A
similar pattern exists when FiO2 was reduced to 30%oxygen (Figures 3C-D). Only when inspired oxygen sup-
ply was further reduced to 21%, the fraction of mito-
chondria within the 0-20 mmHg PO2 range of the RV
MCT60 group (42 ± 13%) increased to values similar as
control (53 ± 5%) (Figure 3E-F). Resetting FiO2 again to
40% restored oxygenation to the initial 40% inspiration
conditions, indicating reversibility of the phenomenon
(Figures 3G-H).
We next analyzed the responses of RV oxygenation to-
wards increases in energy demand by using two different
doses of dobutamine infusions (Figure 4). At a dobuta-
mine dose of 2.5 μg/kg/min the differences observed in
oxygenation between MCT60 and control RV persisted
(Figure 4A-B); only at the highest dobutamine dose did
the fraction of mitochondria in the 0-20 mmHg range in
the MCT RV (32 ± 16%) become similar to that in con-
trol RV (49 ± 10%) (Figure 4C-D).
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Finally, we examined metabolic changes within RV and
LV at the different stages of pulmonary hypertension
(Figure 5). Citrate synthase activity was unaffected by
MCT treatment in RV and LV, indicating similar mito-
chondrial mass among groups. Hexokinase (HK) activity
was increased in the RV of both MCT groups. No
change in HK activity was observed in LV. In contrast,
lactate dehydrogenase (LDH) activity was only increased
in the RV of the MCT30 group, but not in the RV of
the MCT60 group. LDH activity in LV was unaltered(Figure 5). These data indicated a differential response of
glycolytic enzymes to the development of RV failure.
Discussion
Hypoxia at the level of the cardiomyocyte mitochondria
is hypothesized as an important contributing factor in
the development of cardiac failure [2,5,19,20]. A critical
evaluation of this hypothesis has been missing due to
the lack of a technique enabling quantitative measure-
ments of mitochondrial oxygenation within the in vivo
working heart. In the present study, through application
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show that at the initiation of cardiac failure, mitochon-
drial oxygenation is higher (under baseline conditions)
or equal (under decreased oxygen supply or increased
work demand conditions) as compared to healthy hearts.
No decreased cardiac mitochondrial oxygenation was
observed, arguing against hypoxia being an important
contributor to the development of right heart failure.
Mitochondrial oxygenation and cardiac metabolic
signature of RV failure
Our observation of less mitochondria with low oxygen
in the RV failure developing animals, suggests decreased
mitochondrial oxygen consumption in the transition
from compensated hypertrophy towards cardiac failure.
Decreased oxygen consumption has indeed been directly
measured 4-6 wk after MCT administration, although
not in intact hearts but in permeabilized cardiac fibers
or minced heart tissue [19-21]. Suppression of mito-
chondrial metabolism together with increased glycolysis
was recently proposed as intrinsic mechanism underlyingthe development of pulmonary arterial hypertension and
heart failure [11]. This data would suggest that impair-
ments in energy production (ATP synthesis) in RV heart
failure, as reported by different groups [19,22], are mainly
metabolically mediated, and not through impairment
of oxygen delivery. Theoretically, mitoPO2 can also be
elevated as a consequence of increases in oxygen supply
when going from the hypertrophied to the failing condi-
tion. However, such evidence cannot be found in lite-
rature. On the contrary, capillary density or coronary
blood flow or angiogenesis are commonly decreased in
hypertrophy or with the transition towards heart failing
[11,16,23]. The increased mitochondrial PO2 measured
in this study is also not a result from a decrease in mito-
chondrial capacity, since citrate synthase activities were
similar between control and MCT RV. Previous work
from our group also demonstrated unaltered mitochon-
drial capacity in RV of MCT-treated animals [16,24].
We did find elevated HK activities in the hypertrophied
and failing RV, consistent with other studies [25-27].
Interestingly, increases in hexokinase were recently also
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program [28]. The increase in HK is probably an adap-
tive mechanism, attenuating structural and maladaptive
remodelling with pressure-overload [29]. Interestingly,
LDH activity was only increased in the compensated
hypertrophied RV, but not in the failing RV. Thus,
decreased number of mitochondria with low oxygen
tension and loss of LDH increase are the specific meta-
bolic markers observed in the present study that sets
the developing failing RV apart from the compensated
hypertrophied RV. Although increased cardiac HK has
been associated with decreased cardiac oxygen con-
sumption [29-31], or decreased LDH may decrease
oxygen consumption considering lactate as important
substrate for the heart [32,33], further in-depth studies
directed at these metabolic hypotheses are neededbefore any affirmative statements can be made. Alterna-
tively, although not examined in the present study,
mitochondrial oxygen consumption may also decrease
due to cytochrome c oxidase inhibition by NO, which
levels were shown to be increased in congestive heart
failure [12,34]. Irrespective of the exact molecular
mechanism, our novel observation of higher in vivo
mitochondrial oxygenation suggests impaired in vivo
mitochondrial metabolism as a possible trigger for the
development of RV failure.
In the current work the chemical substance MCT
was used to induce pulmonary hypertension; however,
pulmonary hypertension can have several different
etiologies (chronic thromboembolic, pre-versus postca-
pillary pulmonary hypertension, connective tissue dis-
ease, etc.). Although we anticipate that, independent of
the etiology, any increase in pulmonary arterial pres-
sure will increase RV afterload and thereby most likely
start the metabolic, mitochondrial, remodelling phase
as described here for the MCT model, further research
is warranted to state this more definitively for different
pulmonary hypertension etiologies.
Methodological considerations
Under baseline conditions the animals were mechanically
ventilated with 30-40% inspiration oxygen, which is above
the ambient air content of oxygen (21%) with spontan-
eously breathing. The higher inspiration oxygen levels are
necessary to compensate for the known ventilation-
perfusion defects caused by anesthesia and mechanical
ventilation in especially diseased humans and animals
[35,36] and are the recommended inspiration oxygen
levels with mechanical ventilation used in the clinical
arena. Mechanical ventilation in our healthy animals with
a FiO2 of 21% resulted in an arterial tension of appro-
ximately 80 mmHg, below the 100 mmHg normally
obtained with spontaneous breathing, indicating that the
use of ambient air oxygen levels with mechanical ventila-
tion and anesthesia is indeed associated with insufficient
blood oxygenation. In addition, we needed at least a FiO2
of 30% to obtain a physiological normal arterial tension of
100 mmHg in the MCT60 animals. Most importantly,
even with the lower arterial oxygen tension of the
MCT60 animals as compared to healthy controls at 30%
or 40% FiO2, there were still less mitochondria with
pO2 < 20 mmHg in the MCT60 RV, illustrating that the
fewer mitochondria with low oxygen are not simple a
result of higher arterial oxygen in these sick animals.
The present study used the monocrotaline-induced
pulmonary arterial hypertension intervention as a model
to study RV hypertrophy and failure. Because almost all
animal models are not fully mimicking the clinical features
of human pathologies, studies in different models of heart
failure, e.g. infarction- or aortic constriction-induced
Balestra et al. Respiratory Research  (2015) 16:6 Page 9 of 10models, will need to be examined to more definitely
establish whether increased mitochondrial oxygenation
is in general a signature of HF. In addition, although we
did not fully characterise RV function with e.g. echocar-
diography, other studies demonstrated RV dysfunction
with 60 mg/kg MCT at 3-6 weeks after MCT admi-
nistration [11,19,20,37,38]. Together with the reported
decreased body weight and increased mortality in the
present study it is likely that the MCT60 animals at
4 wk after MCT administration are in the critical transi-
tion phase of RV decompensation. However, the use of
full RV function characterization with mitoPO2 mea-
surements is needed in future studies to describe in
more detail the relation between RV dysfunction and
RV mitochondrial oxygenation.
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